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ymptoms compatible with allergic (immunoglobulin E [IgE] mediated) disease are common and have multiple etiologies. Thus, effective treatment depends on clinical evaluation and an accurate diagnosis. According to the American Academy of Allergy, Asthma, and Immunology (AAAAI), treatment measures such as allergen avoidance and pharmacotherapy should be based on positive history and diagnostic testing. 1 Although that report emphasizes the important role of professional referral and skin testing, the use of multiallergen-specific IgE testing by family physicians has been acknowledged as an accurate tool, useful in identifying specific allergen sensitivities and helpful in focusing further investigation and referral. 2, 3 With allergy prevalence estimates of 10% to 30%, antihistamine drugs such as fexofenadine (Allegra), loratadine (e.g., Claritin), and cetirizine (Zyrtec), have gained widespread acceptance as a strategy to help patients cope with allergic symptoms. 4, 5 Positive benefits of prescribed antihistamines for allergic rhinitis include increased airway caliber, improved breathing, and significantly reduced symptoms. 6 Other studies suggest that medications prescribed to treat allergic rhinitis may alleviate symptoms of asthma. 7 While these medications appear to reduce symptoms and improve patient health, consideration must be given to their total cost, estimated at $8.4 billion per year. 8 For some patients, however, the use of allergy medication may not be effective or offer only a short-term solution for an ongoing problem. 9 For example, the authors in one study asserted that although these medications may alleviate symptoms, an accurate diagnosis suggests more appropriate clinical management, less frequent medication changes, and improved quality of life. 10 Decisions to prescribe these medications are usually predicated on clinical evaluation, including patient history and perhaps some diagnostic testing. In the process of patient evaluation, patient history can be subjective and influenced by perceptual interpretation with respect to clinical experience and expectations. Moreover, pertinent information may be selectively filtered or overlooked in the communication process. Besides patient history, diagnostic tools include avoidance, specific allergen challenges, medication trials, and those that indicate immunological sensitization.
11 Successful medication trials with antihistamines are often interpreted as proof of an allergic etiology even though their activity is rather nonspecific. An example of a test that indicates sensitization is the multiallergen-specific IgE test, which contains about 15 different common allergens that identify approximately 98% of the patients with allergic rhinitis. This specific IgE test is highly specific and selective for IgE antibodies to a mixture of the most prevalent inhalant allergens.
Only recently has evidence surfaced to suggest that patient history and symptoms may not align well with the results obtained from diagnostic tests such as skin testing or multiallergen-specific IgE testing. In one study, the accuracy of the diagnosis of a patient for a specific allergic condition by history alone compared with concordant skin testing and specific IgE measurements rarely exceeded 50% and, in some cases, was below 25%. 13 Given this potential for discrepancy between history and true diagnosis, questions arise regarding the existence of similar discrepancies between prescribed antihistamine use and multiallergen-specific IgE testing.
In this study, we investigate whether the patterns of prescribed antihistamine use in a managed care facility were consistent with results obtained from a multiallergen-specific IgE test for allergy. Specifically, the UniCAP Phadiatop is a single laboratory test designed to determine the presence or absence (e.g., positive or negative) of specific IgE to a variety of common inhalant allergens (e.g., grass, ragweed, cat, and mite).
14 In this study, the cut-off point for positivity for the specific IgE assays was 0.35 kUA/L, with test sensitivity and specificity reported at 100%. 14, 15 Test results were categorized as either positive or negative.
II Methods
Prescription claim records for 4,643 patients enrolled in a 115,000-member health plan located in the southeast United States were examined retrospectively by 2 pharmacists to identify patients who received at least 1 prescription for a low-sedating antihistamine (LSA) in tablet or capsule form (cetirizine 5 mg or 10mg, fexofenadine 60 mg, loratadine 10 mg, and all combinations with pseudoephedrine). Of these 4,643 patients, there were 1,343 patients with a diagnosis of allergic rhinitis (ICD-9-CM 477.0, 477.8, and 477.9 for pollen, other allergens, and unspecified, respectively). Antihistamine use was defined Once these patients were identified, a convenience sample yielded 246 patients who completed a consent form and desired confirmation of their allergy diagnosis with a free multiallergenspecific IgE test (Phadiatop by Pharmacia Diagnostics, Current Procedural Terminology Code [CPT] 86005) 17, 18 ( Figure 1 ). Patients were offered a mailed summary of their survey responses and, based on these replies, personalized allergy-management information.
Age and gender were the only demographic data available for the study participants, and there was not a significant difference for age or gender between the convenience sample and the plan enrollees who used at least 1 LSA (N = 1,343; average age = 43.65 years [11.7 SD] for plan enrollees versus N = 246; age = 45.02 years [11.4 SD] for the convenience sample). The chi-square test of independence was used to assess differences between infrequent and frequent users of prescribed LSAs. Values of P<0.05 for a 2-tailed test were considered significant.
II Results
Of the 163 frequent LSA users, 62 (38%) had evidence of specific IgE that would be consistent with a diagnosis of allergy, and 30.1% (25 of 83) of infrequent users also had similar evidence of specific IgE. Results from the chi-square statistical test revealed no significant difference between the observed and expected frequencies among patients undergoing specific IgE testing and prescribed LSA use (χ2 = 1.5; P≤0.225). Thus, our hypothesized relation between prescribed antihistamine use and sensitization status was not supported. However, further examination of the data in Table 1 revealed that 64.6% (159 of 246) of the laboratory-tested group did not have significant levels of specific IgE (the cut-off for positivity for the specific IgE assays was 0.35 kUA/L), and 63.5% (101 of 159) of these patients were classified as frequent LSA users over the last year. Stated differently, approximately two thirds of those patients with records of frequent LSA use were tested as negative for specific IgE.
II Discussion
The initial clinical diagnosis of an allergic condition was supported for 35.4% of the patients who had the multiallergen-specific IgE test. Although the treatment of rhinitis with antihistamines is often used to provide diagnostic evidence of an allergic etiology, it has been estimated that as many as 50% of patients with rhinitis may not have allergic rhinitis. 19, 20 Thus, in some situations, short-term or intermittent use of these medications is warranted to treat conditions such as nasal congestion, rhinorrhea, sneezing, itching, and hyposmia. However, frequent use (3 months or more) of prescribed antihistamines would suggest the need for more specific evaluation or additional follow-up.
The lack of a significant difference in frequent antihistamine use and the presence or absence of inhalant allergy in this patient population suggest that routine history and physical examination may not always provide accurate evidence to discern allergic from nonallergic rhinitis. 5 Considering that the results of this study are consistent with findings from previous reports of confirmed allergy (43%, n= 975), 21, 22 our findings suggest the need for more extensive patient evaluation criteria. Although patients provide a comprehensive overview of their current health status, additional opportunities exist for clinicians in patient screening and evaluation. For example, patients who present with multiple allergic-like symptoms would undergo preliminary evaluation by trained clinicians and practitioners. Decision protocols can be developed and standardized to ascertain whether perceptual differences in judgment have possibly influenced conclusions drawn from the patient history and evaluation. 13 After examining patient history and evidence of allergic etiology, or patients appear unresponsive to medications, objective tests such as the multiallergen-specific IgE test may be performed.
At the time of this study, loratadine was available only by prescription, but the availability of loratadine over the counter (OTC) at year-end 2002 begs examination of the means to attain the optimum cost benefit from verification of true allergy in frequent users of antihistamines. While OTC loratadine costs less than $20 per month of therapy, most drug plans in managed care organizations (MCOs) cover prescription oral antihistamines that have average wholesale prices that range from $75 to $105 for a 30-day supply. 23 The average price paid per spe- Although these costs, to some extent, may be covered by a third-party plan, patients, providers, and MCOs should evaluate short-term and long-term benefits of serum allergen testing. From a managed care perspective, optimal strategies for therapy would begin by accurately identifying patients who would benefit from specific IgE testing. Results from this study suggest that confirmation of allergic disease may be more complex, perhaps involving the cooperation of both family physicians and allergists. Primary care physicians might perform initial evaluation, testing, and treatment involving the short-term use of antihistamines and, with patients, evaluate patient responsiveness to drug therapy. Persistent or more-severe symptoms may require further evaluation and referral. Allergy testing may be more beneficial when patients are stratified by severity and persistence of allergy symptoms, magnitude of direct costs (e.g., physician visits, oral antihistamines), and indirect costs (e.g., diminished productivity). These suggestions present opportunities for managed care physicians and pharmacists to work together efficiently to create an environment to improve patient management through initiatives that focus on diagnostic accuracy. Hence, consideration should be given to the additional benefits of testing and the contribution that appropriate prescribing would make toward improving patient outcomes and possibly reducing health care and social costs.
Limitations
The extent to which patients are affected by allergic rhinitis may be a function of seasonal fluctuations characteristic of the geographic region (southeastern United States) of this MCO. Additionally, survey completion was not designed to necessarily coincide with the annual period during which symptoms were experienced. Hence, the absence of particular symptoms at that time did not preclude the presence of seasonal allergic rhinitis. However, seasonal affects may be of no consequence since the IgE test is unaffected by antihistamine use. Moreover, the presence of IgE is not affected by the season in which the test is performed.
II Conclusions
By far, the most common-but not only-reason for prescribing LSAs is for symptoms with a suspected allergic etiology. Our data suggest that either LSAs are prescribed indiscriminately or that the sequencing of testing and treatment needs further evaluation. Notwithstanding consideration of medication side effects, economic considerations, and the potential for escalating costs associated with the advent of more expensive allergy treatment options (e.g., leukotriene receptor antagonists, antiIgE), assuring the existence of allergic etiology may be more beneficial to patients (e.g., reduced office visits, improved quality of life) and increasingly important to managed care providers. Practitioners and clinicians might use objective means such as multiallergen-specific IgE testing in conjunction with other evidence such as patient symptoms and history to confirm the allergic basis of disease.
